Get the Stockscreener App
1.69
1.81%
0.03
After Hours:
1.69
Okyo Pharma Limited stock is traded at $1.69, with a volume of 85,263.
It is up +1.81% in the last 24 hours and down -11.05% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.66
Open:
$1.69
24h Volume:
85,263
Relative Volume:
0.32
Market Cap:
$86.82M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-10.30
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
-1.74%
1M Performance:
-11.05%
6M Performance:
-25.22%
1Y Performance:
+21.58%
1-Day Range:
$1.6501
$1.73
1-Week Range:
$1.60
$1.79
52-Week Range:
$1.03
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.69 | 85.27M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive financial news
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative
OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - GlobeNewswire
Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World
Piper Sandler Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler - MarketBeat
Piper Sandler initiates OKYO Pharma stock with Overweight rating By Investing.com - Investing.com Nigeria
How OKYO Pharma Limited stock compares to industry benchmarksWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
CEO Moves: Is OKYO Pharma Limited a turnaround story2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
How interest rate cuts could boost OKYO Pharma Limited stockJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Piper Sandler initiates OKYO Pharma stock with Overweight rating - Investing.com South Africa
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target - marketscreener.com
Big Money Moves: How interest rate cuts could boost OKYO Pharma Limited stock2025 Investor Takeaways & Entry and Exit Point Strategies - mfd.ru
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - VisionMonday.com
Small cap wrap: Trust Stamp, HIVE Digital Technologies, OKYO Pharma... - Proactive financial news
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain - Proactive financial news
What risks investors should watch in OKYO Pharma Limited stock2025 Market Sentiment & Technical Entry and Exit Alerts - mfd.ru
Options Flow: Is OKYO Pharma Limited exposed to political riskQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Income Plays: Is Amylyx Pharmaceuticals Inc in accumulation or distribution phaseJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Support Test: Is APWC a strong candidate for buy and holdJuly 2025 Review & Expert Curated Trade Setups - baoquankhu1.vn
Can OKYO Pharma Limited stock deliver sustainable ROEPortfolio Performance Report & Growth Focused Stock Reports - mfd.ru
OKYO Pharma Prices Public Offering at $1.85 per Share - Intellectia AI
OKYO PE Ratio & Valuation, Is OKYO Overvalued - Intellectia AI
Is OKYO Pharma Limited a turnaround storyWeekly Stock Analysis & Reliable Price Breakout Signals - mfd.ru
Small cap wrap: OKYO Pharma, HIVE Digital Technologies, Synchronoss Technologies... - Proactive financial news
Published on: 2026-02-14 12:01:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest - MarketBeat
OKYO Pharma launches underwritten public offering of ordinary shares - MSN
OKYO Pharma announces $20 million public offering of ordinary shares - Investing.com South Africa
OKYO Pharma announces $20 million public offering of ordinary shares By Investing.com - Investing.com Canada
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development - TipRanks
OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com South Africa
OKYO Pharma stock tumbles on $20 million public offering announcement By Investing.com - Investing.com Canada
OKYO Pharma prices $20M offering to fund late-stage eye drug trial - Yahoo Finance
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline - TipRanks
What’s the analyst consensus on OKYO Pharma LimitedOptions Play & Technical Entry and Exit Tips - mfd.ru
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):